Harvoni Expanded Pool Of Treated Hepatitis C Patients, CVS Data Suggest

A report from the CVS Health Research Institute says Harvoni produced 2.5 times more prescriptions the first eight weeks post-launch than Sovaldi yielded in its first eight weeks, but Sovaldi scripts have held steady since Harvoni became available.

The rapid uptake of Gilead Sciences Inc.’s hepatitis C virus therapy Harvoni while prescriptions of the company’s earlier HCV blockbuster Sovaldi hold steady suggests that Harvoni has expanded the treatment pool for HCV, according to a report from the CVS Health Research Institute.

The report notes that although the prescribing rate for Harvoni (sofosbuvir/ledipasvir) surpassed Sovaldi (sofosbuvir) by the end of November, “in...

More from United States

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By 

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

More from North America

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

COVID-19 mRNA Vaccine Labels Now Quantify Myocarditis Risk, But ACIP Wants Other Changes

 
• By 

New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.